Indonesia vs Uganda: Average cost of multi drug-resistant tuberculosis treatment
Indonesia
1,138 constant 2022 US$
in 2024
Uganda
1,209 constant 2022 US$
in 2024
Indonesia rank
41st
Uganda rank
39th
Average cost of multi drug-resistant tuberculosis treatment over time
- Indonesia
- Uganda
How they compare
Uganda currently reports 1,209 constant 2022 US$ against 1,138 constant 2022 US$ in Indonesia, a difference of 71 constant 2022 US$.
That makes Uganda's figure about 1.1 times Indonesia's.
The two have swapped places 3 times across 8 shared years of data; in 2017 it was Indonesia ahead.
Indonesia ranks 41st and Uganda ranks 39th of 92 countries.
Indonesia has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Indonesia | Uganda | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1,463 constant 2022 US$ | 1,210 constant 2022 US$ | 253.33 constant 2022 US$ | Indonesia |
| 2020s | 1,466 constant 2022 US$ | 1,304 constant 2022 US$ | 162.2 constant 2022 US$ | Indonesia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Indonesia or Uganda?
- Uganda, at 1,209 constant 2022 US$ against 1,138 constant 2022 US$ in Indonesia as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Indonesia and Uganda?
- 71 constant 2022 US$, with Uganda ahead.
- How many years of comparable data are there for Indonesia and Uganda?
- 8 years are reported by both, from 2017 to 2024.
- How do Indonesia and Uganda rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Indonesia ranks 41st and Uganda ranks 39th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.